gpt-dict.com

Acetyl-L-Carnitine for Neuropathy

Verdict: Weak, disputed evidence; depends on neuropathy type

Acetyl-L-carnitine has weak, conflicting evidence for neuropathy: it may modestly ease pain in diabetic peripheral neuropathy, but a high-quality trial shows it actually worsens chemotherapy-induced neuropathy. The two situations must never be treated the same, and benefit for diabetic nerve pain remains uncertain.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is weak (Tier C) and explicitly disputed because the evidence points in opposite directions by neuropathy type. For diabetic peripheral neuropathy (DPN), a 2015 meta-analysis (PMID 25751285, n=523) found a significant pain reduction that was larger in diabetic than non-diabetic patients, and pooled industry-sponsored trials (PMID 15616239, n=1257) reported less pain plus nerve regeneration. Mayo Clinic cautiously notes similar findings, especially when treatment starts early.

However, the most rigorous synthesis, a 2019 Cochrane review (PMID 31201734, n=907), rated certainty as VERY LOW and found benefit only above 1500 mg/day, so reliable efficacy is not established. The largest positive trials were industry-funded, and a 2016 active-comparator trial (PMID 27180954, n=232) had no placebo arm, only showing non-inferiority to methylcobalamin.

Crucially, for chemotherapy-induced neuropathy the direction reverses: a high-quality phase III RCT (PMID 23733756, n=409) found acetyl-L-carnitine significantly WORSENED neuropathy (FACT-NTX 1.8 points worse, p=0.01), and ASCO recommends against it. No regulator endorses it for neuropathy: EFSA rejected its cognitive claim, FDA treats it only as a nutrient supplement, and WHO does not list it. Averaging an uncertain DPN signal against documented chemotherapy harm yields an honest C.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
75%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathic Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 25751285 2015 統合分析 n = 523
Finding: Across 4 RCTs (n=523), ALC significantly reduced VAS pain scores versus placebo (MD 1.20, 95% CI 0.68 to 1.72, p<0.00001). The effect was larger in diabetic neuropathy patients (MD 1.47, 95% CI 1.06 to 1.87, p<0.00001) than in non-diabetic patients (MD 0.71, 95% CI -0.01 to 1.43, p=0.05). No severe adverse events related to ALC were reported.
Effect size: MD VAS 1.20 (all); 1.47 (diabetic subgroup); 0.71 NS (non-diabetic subgroup)
View on PubMed
Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy (Cochrane Systematic Review)
PMID: 31201734 2019 Cochrane SR n = 907
Finding: Across 4 RCTs (n=907), ALC showed a modest pain reduction versus placebo at 6-12 months (MD -9.16 on a 0-100 VAS, 95% CI -16.76 to -1.57), with benefit apparently confined to doses above 1500 mg/day. The Cochrane authors rated the certainty of evidence as VERY LOW and concluded they are very uncertain whether ALC reduces pain in DPN; evidence is sparse and effects on function and quality of life are uncertain.
🟠 Limited quality Effect size: MD VAS -9.16/100 (very low certainty)
View on PubMed
Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An Analysis of Two Randomized Placebo-Controlled Trials
PMID: 15616239 2005 隨機對照試驗 n = 1,257
Finding: Pooled analysis of two large industry-sponsored RCTs (n=1257) found the 1000 mg three-times-daily dose significantly reduced pain and improved nerve fiber regeneration and vibratory perception versus placebo in chronic diabetic neuropathy; benefit was greater in patients treated earlier in the disease course.
⚠️ Industry-funded Effect size: Significant pain reduction and improved nerve regeneration at 3000 mg/day
View on PubMed
Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: a multicenter, randomized, double-blind, controlled trial
PMID: 27180954 2016 隨機對照試驗 n = 232
Finding: In 232 patients with DPN, ALC 500 mg three times daily was non-inferior to methylcobalamin in improving neuropathic symptoms and neurophysiological parameters over 24 weeks, and was well tolerated. This is a non-inferiority design without a placebo arm, so it cannot establish absolute efficacy.
Effect size: Non-inferior to methylcobalamin (no placebo comparison)
View on PubMed
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy
PMID: 23733756 2013 隨機對照試驗 n = 409
Finding: COUNTER-EVIDENCE / HARM SIGNAL: In 409 breast cancer patients (208 ALC, 201 placebo), ALC did not prevent and in fact WORSENED chemotherapy-induced peripheral neuropathy. At 24 weeks FACT-NTX scores were 1.8 points lower (worse) with ALC (95% CI -3.2 to -0.4, p=0.01), and significantly more ALC patients had clinically meaningful neuropathy worsening (38% vs 28%, p=0.05). The harm persisted over long-term follow-up.
🟢 High quality Government Effect size: FACT-NTX 1.8 points WORSE with ALC at 24 weeks (p=0.01) - harm
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
NUTRIENT SUPPLEMENT [21 CFR 170.3(o) technical effect — substance: Carnitine / L-carnitine / Levocarnitine, CAS 541-15-1] source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
形態屬膠囊狀、錠狀且標示有每日食用限量之食品，在每日食用量中，L-肉鹼（L-carnitine）總含量不得高於 2 公克。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
In a few studies, people with diabetic neuropathy who took acetyl-L-carnitine supplements had less pain and improvements in their ability to perceive vibrations, as well as improvements in nerve function tests. Some of these studies suggest that acetyl-L-carnitine eases pain better when people start taking it soon after diabetic neuropathy begins. source↗
L5e Specialty Society (condition-mapped)
Cautious
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-neuropathy-INT-acetyl-l-carnitine-001 繁體中文版 →